Pfizer CEO on moving beyond COVID vaccines to become a leader in cancer and obesity treatments
WASHINGTON — Two years ago, Pfizer was the envy of the pharmaceutical world, with more than $100 billion in annual sales from its COVID-19 vaccine and antiviral Paxlovid. Today, CEO Albert Bourla is trying to turn the page from that success story, which has turned into more of a financial headache for the global drugmaker. … Read more
